Rigel Pharmaceuticals (FRA:RI2) Long-Term Debt: €13.0 Mil (As of Mar. 2026)


FRA:RI2 Rigel Pharmaceuticals Inc FRA:RI2
76 GF Score
Price €34.52
GF Value €22.72
! 7 Warning Signs
View Full Analysis

What is Rigel Pharmaceuticals Long-Term Debt?

Rigel Pharmaceuticals FRA:RI2 +1.38% 76 Long-Term Debt is €13.0 Mil as of Mar. 2026. GuruFocus rates FRA:RI2 with a GF Score™ of 76/100 and a GF Value™ of €22.72. The stock has 7 warning signs investors should review.

Rigel Pharmaceuticals's Long-Term Debt for the quarter that ended in Mar. 2026 was €13.0 Mil.

Rigel Pharmaceuticals's quarterly Long-Term Debt declined from Sep. 2025 (€25.5 Mil) to Dec. 2025 (€19.2 Mil) and declined from Dec. 2025 (€19.2 Mil) to Mar. 2026 (€13.0 Mil).

Rigel Pharmaceuticals's annual Long-Term Debt increased from Dec. 2023 (€48.0 Mil) to Dec. 2024 (€50.1 Mil) but then declined from Dec. 2024 (€50.1 Mil) to Dec. 2025 (€19.2 Mil).

Rigel Pharmaceuticals  (FRA:RI2) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Rigel Pharmaceuticals Long-Term Debt Related Terms

Rigel Pharmaceuticals Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Rigel Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rigel Pharmaceuticals Long-Term Debt Chart

Rigel Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.62 37.24 48.03 50.05 19.20

Rigel Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.56 32.47 25.53 19.20 12.97
FRA:RI2
76GF Score
Rigel Pharmaceuticals Inc FRA:RI2
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €13.0 Mil mean?
Rigel Pharmaceuticals (FRA:RI2) has a Long-Term Debt of €13.0 Mil as of Mar. 2026.
Is Rigel Pharmaceuticals' Long-Term Debt too high?
Rigel Pharmaceuticals' current Long-Term Debt is €13.0 Mil. Overall, Rigel Pharmaceuticals has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' Long-Term Debt compare to CADL and IMMX?
Rigel Pharmaceuticals' Long-Term Debt of €13.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Rigel Pharmaceuticals's current Long-Term Debt is €13.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Rigel Pharmaceuticals (FRA:RI2) has a current Long-Term Debt of €13.0 Mil. The stock's GF Value™ is €22.72, compared to a current price of €34.52 — trading 51.9% above its estimated fair value. The current Long-Term Debt is €13.0 Mil. Rigel Pharmaceuticals' overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current Long-Term Debt is €13.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?

Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued. The current stock price of €34.52 is trading 51.9% above its estimated GF Value™ of €22.72.

Key valuation signals for FRA:RI2:

  • Long-Term Debt: €13.0 Mil
  • GF Value™: €22.72 vs. price of €34.52 (51.9% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rigel Pharmaceuticals Business Description

Other Exchanges RIGL:USA
Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
76GF Score

Get the complete analysis for FRA:RI2

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€34.52
Price
€22.72
GF Value